July 14th 2025
FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.
June 23rd 2025
Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.
ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.
June 19th 2025
Your daily dose of the clinical news you may have missed.
June 18th 2025
Monu Khanna, MD: Essential Lifestyle Changes for Managing Obesity and Cardiometabolic Risk Factors
9 Drugs Approved for Primary Care: Q2 2025
Review 9 new FDA-approved drugs that may soon find a place in your prescribing routine, including new treatments for migraine, CSU, RSV, and more.
Validation Study of SANSA Home Sleep Apnea Test Published in Frontiers in Neurology, Huxley Medical Announces
Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.
Universal Low-Dose Aspirin Prescribing Strategy May be Beneficial for Preeclampsia Prevention
Research presented at ACOG 2025 showed 99% of pregnant women included in the analysis were eligible for aspirin, per ACOG guidelines.
DASH4D Diet Reduces BP by 4.6 mm Hg in Adults with T2D on Maximal Antihypertensive Therapy
For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.
George Medicines Announces FDA Approval of Polypill for Treatment of Hypertension in Adults
The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.
High-Quality Macronutrients Key to Cardiovascular Risk Reduction, Large Cohort Study Finds
Research reveals that the quality of foods in low-carb and low-fat diets significantly impacts heart health, emphasizing whole, plant-based options.
Coexisting Hypertension and Type 2 Diabetes in US Adults Doubled Over 2 Decades: New Study
Adults with both HTN and T2D had more than twice the risk of all-cause mortality and nearly three times the risk of cardiovascular mortality, according to new data.
High-Quality Carbohydrates in Midlife Linked to Healthier Aging in Women
For every 10% increase in energy from high-quality carbohydrates, the odds of healthy aging rose by 31%, according to an analysis of data from the Nurse's Health Study.
Combined Oral Contraceptive Use May Triple the Risk of Cryptogenic Stroke in Young Women
ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.
Semaglutide Linked to Reduced Risk for MACE Months Before Weight Loss Begins: Post Hoc Analysis
Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.
FDA Greenlights Low-Dose Clorthalidone (12.5 mg) for Treatment of Hypertension in Adults
Low-dose clorthalidone offers clinicians a new option for initiating treatment that may mitigate well-known metabolic adverse effects.
Foluso Fakorede, MD: Racial Disparities in PAD Amputation Rates
Rates of amputation in Black Americans with peripheral arterial disease are 3-times higher than that of their White counterparts. Dr Fakorede, discusses, here.
Clinically Validated Blood Test Identifies Preeclampsia Risk Early in Pregnancy, New Study Shows
A simple RNA-based blood test can identify the risk of hypertensive disorders in pregnancy months before symptoms appear, researchers reported.
PAD Risk Amplifiers and Screening Strategies: A Talk with Foluso Fakorede, MD
ACP 2025: Dr Fakorede outlines PAD risk amplifiers, polyvascular disease connections, and when to screen using ABI, TBI, or exercise testing in high-risk patients.
Adolescent Hyperglycemia, Insulin Resistance Drive Early Cardiac Structural Changes, Novel Cohort Study Finds
Persistent hyperglycemia between ages 17 and 24 tripled the risk of left ventricular hypertrophy and did so 5 times faster among young women, a new study found.
Peripheral Artery Disease in Primary Care: Expert Insights on Recognition & Risk Factors
ACP 2025: Foluso Fakorede, MD, discusses the importance of recognizing and screening for peripheral artery disease in primary care.
High Blood Pressure Advisory in EHR Improves Hypertension Diagnosis, Control Across a Primary Care Network
An EHR advisory that combined alerts to medical assistants with escalation to clinicians increased likelihood of hypertension control by a mean 18% per month.
Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose
Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection
The CART ring was superior to the Apple Watch in automated AF detection with fewer unclassified ECGs, but neither device should serve as a definitive diagnostic tool.
Tirzepatide Improves Heart Failure Symptoms and Renal Function in People with Obesity, CKD
ACC 2025. Tirzepatide improved HF symptoms and renal function in patients with obesity-related HFpEF, regardless of CKD status, according to new findings from the SUMMIT trial.
Diagnosis of Atrial Fibrillation: A Guideline Topline
This AF guideline topline offers an at-a-glance look at the most recent ACC/AHA guidance on diagnosis of the arrhythmia.
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study
Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
Low-Dose Colchicine 0.5 mg Reduced Total Plaque Volume in Stable CAD vs Placebo
Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.
Oral Semaglutide Lowers Risk of MACE 14% in High-Risk Adults: Final Phase 3 SOUL Trial Readout
ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.
Women's Heart Health: 5 Studies from ACC.25
The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.
Better CV Health Tied to Lower Neurodegeneration Risk: Daily Dose
Long COVID's Long Road: A Year 5 Update with Noah Greenspan DPT, PT, CCS, EMT-B
Five years after the COVID-19 pandemic was declared, the protean syndrome dubbed long COVID continues to affect millions; Greenspan is dedicated to helping.
Maternal Mortality Due to Cardiovascular Disease More Than Doubles in the US
ACC 2025: Black women and women in Southern states faced significantly higher rates of maternal mortality, according to a new study.
Marijuana Use Tied to Increased Risk for Myocardial Infarction in People Aged 50 Years and Younger
Cannabis users had a more than sixfold increased risk of MI compared to non-users, according to a new study.